Mabwell (Shanghai) Bioscience Co., Ltd.
Research Mabwell (Shanghai) Bioscience Co., Ltd. (2493.HK) on Bullrun: market cap HKD 8.55B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2493.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 8.55B
- Financial periodQ2 2026
- RevenueCNY 185.04M
- Net income-CNY 279.76M
- Free cash flow-CNY 291.45M
- Gross margin75.0%
Valuation Snapshot
latest market cap is HKD 8.55B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 8.55B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Mabwell (Shanghai) Bioscience Co., Ltd.
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection;
ETFs that hold Mabwell (Shanghai) Bioscience Co., Ltd.
US-listed ETFs
Mabwell (Shanghai) Bioscience Co., Ltd. is held by 6 US-listed ETFs, going by the latest portfolios they filed with the SEC, most traded first:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| State Street SPDR Portfolio Emerging Markets ETF (SPEM) | 0.01% | 0.07% |
| Vanguard FTSE All-World ex-US Small-Cap Index Fund ETF Shares (VSS) | <0.01% | 0.06% |
| Vanguard ESG International Stock ETF (VSGX) | <0.01% | 0.10% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Mabwell (Shanghai) Bioscience Co., Ltd.'s market cap?
Mabwell (Shanghai) Bioscience Co., Ltd.'s market capitalization is HKD 8.55B.
What does Mabwell (Shanghai) Bioscience Co., Ltd. do?
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection; and JUNMAIKANG, an autoimmune Adalimumab injection.